MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

Key facts

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Intervention

PD-1 monoclonal antibody consolidation therapy(drug)

Enrollment

102 target

Eligibility

18 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Cancer hospital, CAMS, Beijing, Beijing Municipality, China

Collaborators

Peking University Cancer Hospital & Institute · Hebei Medical University Fourth Hospital · Tianjin Medical University Cancer Institute and Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Carcinoma of esophagus

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06990178
  Adaptive Neoadjuvant Therapy for Esophageal Cancer
  Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
• RECRUITINGNCT07464470
  Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
  Blokhin's Russian Cancer Research Center
• RECRUITINGNANCT07307560
  High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
  Zhejiang University
• ENROLLING BY INVITATIONEARLY PHASE1NCT07371247
  Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE3NCT07217704
  Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
  SOFIE
• ACTIVE NOT RECRUITINGPHASE2NCT07339488
  Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
  Chuangzhen Chen
• RECRUITINGPHASE2NCT07205731
  Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
  University Hospital, Clermont-Ferrand
• RECRUITINGPHASE2NCT07071103
  Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
  Chuangzhen Chen

See all trials for Carcinoma of esophagus →